Bak-Fredslund Kirstine P, Lykke Eriksen Peter, Munk Ole L, Villadsen Gerda E, Keiding Susanne, Sørensen Michael
Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark.
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Noerrebrogade 44, DK-8000, Aarhus, Denmark.
EJNMMI Res. 2017 Aug 29;7(1):71. doi: 10.1186/s13550-017-0320-1.
PET/CT with the radioactively labelled galactose analogue 2-F-fluoro-2-deoxy-D-galactose (F-FDGal) can be used to quantify the hepatic metabolic function and visualise regional metabolic heterogeneity. We determined the day-to-day variation in humans with and without liver disease. Furthermore, we examined whether the standardised uptake value (SUV) of F-FDGal from static scans can substitute the hepatic systemic clearance of F-FDGal (K , mL blood/min/mL liver tissue/) quantified from dynamic scans as measure of metabolic function. Four patients with cirrhosis and six healthy subjects underwent two F-FDGal PET/CT scans within a median interval of 15 days for determination of day-to-day variation. The correlation between K and SUV was examined using scan data and measured arterial blood concentrations of F-FDGal (blood samples) from 14 subjects from previous studies. Regional and whole-liver values of K and SUV along with total metabolic liver volume and total metabolic liver function (total SUV, average SUV multiplied by total metabolic liver volume) were calculated.
No significant day-to-day differences were found for K or SUV. SUV had higher intraclass correlation coefficients than K (0.92-0.97 vs. 0.49-0.78). The relationship between K and SUV was linear. Total metabolic liver volume had non-significant day-to-day variation (median difference 50 mL liver tissue; P = 0.6). Mean total SUV in healthy subjects was 23,840 (95% CI, 21,609; 26,070), significantly higher than in the patients (P < 0.001).
The reproducibility of F-FDGal PET/CT was good and SUV can substitute K for quantification of hepatic metabolic function. Total SUV of F-FDGal is a promising tool for quantification of metabolic liver function in pre-treatment evaluation of individual patients.
使用放射性标记的半乳糖类似物2-F-氟-2-脱氧-D-半乳糖（F-FDGal）的PET/CT可用于量化肝脏代谢功能并可视化区域代谢异质性。我们确定了患有和未患有肝病的人群中的每日变化。此外，我们研究了静态扫描中F-FDGal的标准化摄取值（SUV）是否可以替代动态扫描中量化的F-FDGal的肝脏全身清除率（K，mL血液/分钟/mL肝组织）作为代谢功能的指标。四名肝硬化患者和六名健康受试者在中位间隔15天内接受了两次F-FDGal PET/CT扫描，以确定每日变化。使用先前研究中14名受试者的扫描数据和测量的F-FDGal动脉血浓度（血样）检查K与SUV之间的相关性。计算K和SUV的区域和全肝值以及总代谢肝体积和总代谢肝功能（总SUV，平均SUV乘以总代谢肝体积）。
K或SUV未发现显著的每日差异。SUV的组内相关系数高于K（0.92 - 0.97对0.49 - 0.78）。K与SUV之间的关系是线性的。总代谢肝体积的每日变化不显著（中位差异50 mL肝组织；P = 0.6）。健康受试者的平均总SUV为23,840（95% CI，21,609；26,070），显著高于患者（P < 0.001）。
F-FDGal PET/CT的可重复性良好，SUV可替代K用于量化肝脏代谢功能。F-FDGal的总SUV是个体患者治疗前评估中量化代谢肝功能的有前途的工具。
